Science & Enterprise subscription

Please share Science & Enterprise

RSS
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Exosome Technology Acquired for TBI, Stroke Therapies

Stroke circulation

A company developing therapies for brain injuries and neurodegenerative disorders is acquiring the rights to a process that treats these conditions with pieces of RNA transferred in tiny containers call exosomes. . . . → Read More: Exosome Technology Acquired for TBI, Stroke Therapies

UC-Berkeley Gains U.S. Crispr-Cas9 Patent

Editing DNA

University of California received a patent for its genome editing technology known as Crispr, with the most widely used editing enzyme called Cas9. . . . → Read More: UC-Berkeley Gains U.S. Crispr-Cas9 Patent

$850M Deal Kicks Off RNA Vaccine Research

RNA strand illustration

Drug maker Sanofi is partnering with biotechnology company Translate Bio to develop vaccines against infectious diseases from messenger RNA, material transcribed from genetic codes in DNA. . . . → Read More: $850M Deal Kicks Off RNA Vaccine Research

Patent Awarded for Nasal Delivered Cancer Immunotherapy

U.S. Patent and Trademark Office

A technology for cancer therapies that harnesses the immune system with nanoscale droplets suspended in an emulsion and delivered through the nose received a U.S. patent. . . . → Read More: Patent Awarded for Nasal Delivered Cancer Immunotherapy

Univ. Licenses Barrett’s Esophagus Detection Device

Cancer magnified

A medical device company is licensing a minimally-invasive technology developed in university labs for detection of Barrett’s esophagus, a condition that often leads to esophageal cancer. . . . → Read More: Univ. Licenses Barrett’s Esophagus Detection Device

Genetic Repair Company Starts-Up, Gains $87 Million

David Liu

A company is getting underway to develop therapies that extend genome editing to repair genetic disruptions, not just remove them from DNA. . . . → Read More: Genetic Repair Company Starts-Up, Gains $87 Million

Genentech Gains Microbe Drug Discovery Tech in $1B Deal

Collecting soil samples

Biotechnology company Genentech is licensing a process from a start-up enterprise that discovers small molecule drugs from naturally occurring microbes found in soil. . . . → Read More: Genentech Gains Microbe Drug Discovery Tech in $1B Deal

Lilly, Cell Implants Start-Up Partner on Diabetes

Eli Lilly and Company is licensing a technology for implanting pancreatic beta cells in people with type 1 diabetes, from Sigilon Therapeutics Inc., an enterprise making implants of live cells to treat chronic diseases. . . . → Read More: Lilly, Cell Implants Start-Up Partner on Diabetes

New Company Acquires Off-the-Shelf T-Cell Cancer Therapies

A new enterprise is formed to develop treatments for cancer using donated T-cells from the immune system, rather than the patient’s own T-cells, engineered to attack cancer cells. . . . → Read More: New Company Acquires Off-the-Shelf T-Cell Cancer Therapies

Cough Suppressant Produced from Engineered Yeast Cells

A bioengineering group created a process for producing a cough suppressant in the lab, usually derived from opium poppies, but instead from genetically modified brewer’s yeast. . . . → Read More: Cough Suppressant Produced from Engineered Yeast Cells